Rondy, MarcGherasim, AlinCasado, ItziarLaunay, OdileRizzo, CaterinaPitigoi, DanielaMickiene, AukseMarbus, Sierk DMachado, AusendaSyrjänen, Ritva KPem-Novose, IvaHorváth, Judith KrisztinaLarrauri, AmparoCastilla, JesúsVanhems, PhilippeAlfonsi, ValeriaIvanciuc, Alina EKuliese, Monikavan Gageldonk-Lafeber, RianneGomez, VeronicaIkonen, NiinaLovric, ZvjezdanaFerenczi, AnnamáriaMoren, AlainI-MOVE+ hospital working group2018-02-262018-02-262017-10-12Euro Surveill. 2017 Oct;22(41):1-6. doi: 10.2807/1560-7917.ES.2017.22.41.17-006451025-496Xhttp://hdl.handle.net/10400.18/5071Members of the I-Move+hospital working group - Portugal: B. Nunes, I. Kislaya, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal).In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.engA(H3N2)InfluenzaCases Control;ElderlyHospitalisationVaccine EffectivenessVacina AntigripalCuidados de SaúdeEfetividade da Vacina Antigripaljournal article10.2807/1560-7917.ES.2017.22.41.17-00645